These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16219399)

  • 21. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
    Kelleher AD; Puls RL; Bebbington M; Boyle D; Ffrench R; Kent SJ; Kippax S; Purcell DF; Thomson S; Wand H; Cooper DA; Emery S
    AIDS; 2006 Jan; 20(2):294-7. PubMed ID: 16511428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
    Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
    Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of DNA vaccine-induced immune responses by a 72-bp element from SV40 enhancer.
    Li HS; Liu Y; Li DF; Zhang RR; Tang HL; Zhang YW; Huang W; Liu Y; Peng H; Xu JQ; Hong KX; Shao YM
    Chin Med J (Engl); 2007 Mar; 120(6):496-502. PubMed ID: 17439744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms.
    Ellenberger D; Li B; Smith J; Yi H; Folks T; Robinson H; Butera S
    Virology; 2004 Feb; 319(1):118-30. PubMed ID: 14967493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
    Bråve A; Hinkula J; Cafaro A; Eriksson LE; Srivastava IK; Magnani M; Ensoli B; Barnett SW; Wahren B; Rollman E
    Vaccine; 2007 Sep; 25(39-40):6882-90. PubMed ID: 17707956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
    Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
    Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
    McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
    AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.
    Wang S; Kennedy JS; West K; Montefiori DC; Coley S; Lawrence J; Shen S; Green S; Rothman AL; Ennis FA; Arthos J; Pal R; Markham P; Lu S
    Vaccine; 2008 Feb; 26(8):1098-110. PubMed ID: 18243434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electroporation-mediated administration of candidate DNA vaccines against HIV-1.
    Vasan S
    Methods Mol Biol; 2014; 1121():291-307. PubMed ID: 24510833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen.
    Ramirez K; Barry EM; Ulmer J; Stout R; Szabo J; Manetz S; Levine MM; Pasetti MF
    Hum Gene Ther; 2008 May; 19(5):522-31. PubMed ID: 18507515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming.
    Nimal S; McCormick AL; Thomas MS; Heath AW
    Vaccine; 2005 Jun; 23(30):3984-90. PubMed ID: 15917120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and ethical consideration of AIDS vaccine.
    Veljkovic V; Prljic J; Veljkovic T
    Int Rev Immunol; 2004; 23(5-6):465-86. PubMed ID: 15370278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.